Dementia
MONDO:0001627Loss of intellectual abilities interfering with an individual's social and occupational functions. Causes include Alzheimer's disease, brain injuries, brain tumors, and vascular disorders.
Also known as: dementia, dementia (disease)
1603 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Alzheimer's agitation drug safety trial ends early
Disease control TerminatedThis study tested the long-term safety of AXS-05, a combination of dextromethorphan and bupropion, for treating agitation in people with Alzheimer's disease. It enrolled 139 participants who had completed earlier studies. The trial was terminated early, so the full safety picture…
Phase: PHASE3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Alzheimer's drug ALZ-801 tested Long-Term in High-Risk group
Disease control TerminatedThis study looked at the long-term safety and effects of ALZ-801, a tablet taken twice daily, in 163 people with early Alzheimer's disease who have the APOE4/4 gene. Participants had already completed a previous phase 3 study. The goal was to see if the drug could slow cognitive …
Phase: PHASE3 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Alzheimer's drug trial halted early – no breakthrough yet
Disease control TerminatedThis study tested an experimental drug called SHR-1707 in people with mild memory problems or mild Alzheimer's disease. The goal was to see if it could safely reduce harmful protein clumps in the brain. The trial was stopped early, and it is not expected to cure the disease.
Phase: PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Alzheimer's drug TB006 safety study halted early
Disease control TerminatedThis study looked at the long-term safety of an experimental drug called TB006 (oloctinebart) in people with Alzheimer's disease. It included 119 participants who had either completed a previous TB006 study or were new to the drug. The study was terminated early, so the full safe…
Phase: PHASE2 • Sponsor: TrueBinding, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Alzheimer's drug trial halted early: what happened?
Disease control TerminatedThis early-stage study tested a new drug, ADEL-Y01, in healthy volunteers and people with mild Alzheimer's or mild cognitive impairment. The goal was to check safety and how the drug moves through the body. The trial was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Alzheimer's Disease Expert Lab (ADEL), Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Alzheimer's drug trial halted early after only 8 volunteers
Disease control TerminatedThis study tested a drug called PrimeC in people with mild to moderate Alzheimer's disease. The goal was to see if it is safe and if it helps with thinking and daily activities. The study was stopped early and only 8 people took part, so results are very limited.
Phase: PHASE2 • Sponsor: NeuroSense Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Alzheimer's Tau-Targeting antibody trial halted midway
Disease control TerminatedThis study tested an experimental antibody called JNJ-63733657 in 523 people with early Alzheimer's disease. The antibody aims to clear tau protein clumps in the brain, which are linked to cognitive decline. Participants received either the antibody or a placebo by IV infusion. T…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Brain steroid injection tested for Alzheimer's – but trial halted early
Disease control TerminatedThis early study tested a weekly injection of allopregnanolone, a natural brain steroid, in 6 people with early Alzheimer's or mild cognitive impairment. The goal was to find a safe dose and check for side effects. The trial was terminated early, so we have limited information on…
Phase: PHASE1 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Alzheimer's drug extension trial halted early — what we know
Disease control TerminatedThis study gave Alzheimer's patients who had already completed earlier XPro1595 trials an extra 55 to 74 weeks of the drug to check long-term safety and effects on memory and brain health. Only 11 people took part, and the trial was terminated early, so the findings are limited. …
Phase: PHASE2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Alzheimer's drug AL002 safety trial ends early
Disease control TerminatedThis study was a long-term extension of an earlier trial, testing the safety and tolerability of AL002 in 197 people with early Alzheimer's disease. Participants received the drug by IV infusion. The trial was terminated, meaning it stopped before completion, so the full safety a…
Phase: PHASE2 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Early safety trial of ION269 for Alzheimer's in down syndrome ends after just one participant
Disease control TerminatedThis early-stage study tested a drug called ION269 in adults with Down syndrome who also showed signs of Alzheimer's disease. The goal was to check if the drug was safe and tolerable when injected into the spinal fluid. Only one person took part, and the study was stopped early, …
Phase: PHASE1 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Neurodegenerative drug study ends early after only 17 participants
Disease control TerminatedThis study was designed to let people who had already taken latozinemab in an earlier study continue receiving the drug. Only 17 people took part, and the study was stopped early. The goal was to track safety and how long people stayed on treatment, not to test if the drug could …
Phase: PHASE3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Hope for genetic dementia: AL001 trial ends early
Disease control TerminatedThis phase 3 study tested a drug called AL001 in 119 people who carry a mutation in the progranulin gene, putting them at high risk for or already diagnosed with frontotemporal dementia. The goal was to see if AL001 could slow the worsening of memory, behavior, and language probl…
Phase: PHASE3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Alzheimer's drug SPG302 safety study ends early
Disease control TerminatedThis study aimed to check the long-term safety and effects of a daily pill called SPG302 in people with mild-to-moderate Alzheimer's disease. It included 12 participants who had already been in a previous SPG302 study. The study was terminated early, so results are limited.
Phase: PHASE2 • Sponsor: Spinogenix • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Alzheimer's drug trial halted early – what we know
Disease control TerminatedThis study tested a drug called varoglutamstat (PQ912) in people with early Alzheimer's disease. The goal was to see if it is safe and if it could slow memory and thinking problems. The trial was stopped early, so we have less information than planned. About 112 people took part,…
Phase: PHASE2 • Sponsor: Vivoryon Therapeutics N.V. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Alzheimer's drug trial halted early: what happened?
Disease control TerminatedThis study tested an experimental drug called REM0046127 in people with mild to moderate Alzheimer's disease. The goal was to see if it was safe and how it affected brain chemicals and brain wave activity. The trial was stopped early and included only 14 participants instead of t…
Phase: PHASE2 • Sponsor: reMYND • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Eczema drug trial halted early: what we know
Disease control TerminatedThis study tested an experimental drug called IMG-007 in 13 adults with moderate-to-severe atopic dermatitis (eczema) who did not get enough relief from topical treatments. The main goal was to check the drug's safety, and researchers also looked at how the body processes it and …
Phase: PHASE1, PHASE2 • Sponsor: Inmagene LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Halted gene therapy study raises questions for AMN patients
Disease control TerminatedThis early-stage trial tested a gene therapy called SBT101 for adrenomyeloneuropathy (AMN), a rare nerve disease that causes walking difficulties. Eight adults received either the therapy or a sham procedure. The study was terminated early, so we have limited data on safety and e…
Phase: PHASE1, PHASE2 • Sponsor: SwanBio Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Alzheimer's agitation drug trial halted early
Disease control TerminatedThis study tested a drug called AVP-786 to see if it could safely reduce agitation in people with Alzheimer's dementia over the long term. It was an extension of earlier studies, enrolling over 1,100 participants who had already completed a prior trial. However, the study was ter…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Alzheimer's drug simufilam trial halted Mid-Study
Disease control TerminatedThis study tested a drug called simufilam in over 1,000 people with mild-to-moderate Alzheimer's disease. Participants took either 50 mg, 100 mg, or a placebo twice daily for 76 weeks. The goal was to see if simufilam could slow memory loss and help with daily activities. However…
Phase: PHASE3 • Sponsor: Cassava Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Eye test may spot Alzheimer's early, study finds
Diagnosis TerminatedThis study explored whether a special eye scan (hyperspectral retinal imaging) can detect beta-amyloid, a protein linked to Alzheimer's disease, in the retina. Researchers aimed to see if this non-invasive test could distinguish people with Alzheimer's from healthy individuals. T…
Phase: NA • Sponsor: Center for Eye Research Australia • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Neck-Worn swallow detector fails key test
Diagnosis TerminatedThis study tested a wearable device that sits on the neck to detect swallowing problems in people with conditions like stroke, Parkinson's, multiple sclerosis, Alzheimer's, or dementia. The device was compared to a standard X-ray test. Unfortunately, the device did not meet the a…
Phase: NA • Sponsor: Société des Produits Nestlé (SPN) • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Can a headband spot Alzheimer's? new study tests brain wave device
Diagnosis TerminatedThis study tested whether a wearable EEG device can help doctors diagnose Alzheimer's disease and mild cognitive impairment. Researchers compared brain wave data from the EEG with standard memory and thinking tests in 148 participants. The goal was to see if the EEG could improve…
Sponsor: Boston University • Aim: Diagnosis
Last updated Jun 27, 2026 08:04 UTC
-
Mental health sessions may boost vaccine uptake in latinx communities
Prevention TerminatedThis study tested whether adding vaccine discussions to routine behavioral health visits could reduce hesitancy and increase COVID-19 and flu shots among Latinx adults with mental illness. Clinicians used motivational interviewing and could offer a warm handoff to a nurse for vac…
Phase: NA • Sponsor: Boston College • Aim: Prevention
Last updated Jun 26, 2026 17:00 UTC
-
New Alzheimer's pill shows promise in Mid-Stage trial
Symptom relief TerminatedThis study tests whether adding MK-1167 to standard Alzheimer's treatment can improve memory and thinking in people with mild to moderate Alzheimer's dementia. About 350 participants will receive either MK-1167 or a placebo for 24 weeks. Researchers will measure changes in cognit…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Smartphone app aims to ease burden for hispanic dementia caregivers
Symptom relief TerminatedThis study tests a mobile telehealth app called Brain CareNotes designed to help unpaid Hispanic caregivers manage challenging behaviors in people with Alzheimer's or related dementias. The app offers coaching and tools to handle symptoms like agitation or wandering. Researchers …
Phase: NA • Sponsor: Indiana University • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Experimental drug K0706 tested for lewy body dementia
Symptom relief TerminatedThis study looked at whether a drug called K0706 is safe and tolerable for people with Dementia with Lewy Bodies (DLB). Researchers planned to give 45 participants either a low dose, high dose, or placebo for 12 weeks, then check for side effects and measure changes in brain and …
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Dementia agitation drug trial halted after just 5 patients
Symptom relief TerminatedThis study tested a fast-dissolving film (BXCL501) placed under the tongue to quickly reduce severe agitation in older adults with dementia. The trial aimed to enroll many participants but was stopped early after only 5 people joined. Because it ended so soon, we cannot draw reli…
Phase: PHASE2 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Experimental drug aims to curb disinhibition in dementia patients
Symptom relief TerminatedThis study tested a drug called AVP-786 to see if it could safely reduce disinhibition—impulsive or inappropriate behavior—in people with neurodegenerative disorders like Alzheimer's or frontotemporal dementia. The trial planned to include many participants but was terminated ear…
Phase: PHASE2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Touchscreen device aims to give voice to dementia patients
Symptom relief TerminatedThis study tested a personalized touchscreen device (My PATI) to help people with Alzheimer's or related dementias communicate their care preferences. The goal was to improve quality of life for both patients and their caregivers. The study was terminated early, so results are li…
Phase: NA • Sponsor: Florida International University • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New drug aimed at treating apathy in dementia patients tested
Symptom relief TerminatedThis study tested a drug called CVL-871 to see if it is safe and can help reduce apathy (lack of motivation or interest) in people with dementia. The trial included 41 participants with mild to moderate dementia and clinically significant apathy. The main goal was to check for si…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Could a Head-Zap at home boost your brain?
Symptom relief TerminatedThis study tested whether a gentle, non-invasive brain stimulation technique (tDCS) done at home, along with computer-based brain games, could improve thinking and language skills in people with primary progressive aphasia, mild cognitive impairment, or dementia. Participants use…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Sleep therapy tested for Alzheimer's brain fog
Symptom relief TerminatedThis study tested a behavioral program using bright light therapy and sleep coaching to improve sleep and thinking in older adults with mild cognitive impairment or mild Alzheimer's. Only 15 people were enrolled before the study was stopped early. The goal was to see if the progr…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Light helmet for Alzheimer's shows promise, but study cut short
Symptom relief TerminatedThis pilot study tested a special helmet and abdominal panel that shines near-infrared light and uses a static magnetic field on people with mild-to-moderate Alzheimer's disease. The goal was to see if it could safely improve memory and thinking. The study planned to enroll 60 pa…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
App aims to tame chemo side effects in breast cancer
Symptom relief TerminatedThis study tested a digital health app called medidux™ in 196 people with HER2-positive breast cancer. The app was used for up to 16 weeks during chemotherapy to help track and manage side effects. The goal was to see if using the app reduced the number of severe side effects. Ho…
Phase: NA • Sponsor: Palleos Healthcare GmbH • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Robot seal calms dementia patients during care
Symptom relief TerminatedThis study tested whether a robotic seal named PARO could help elderly people with moderate to severe memory problems feel calmer during daily care like bathing. The robot was used for a few minutes before and during care, twice a week for 16 weeks. The goal was to see if it redu…
Phase: NA • Sponsor: Centre Hospitalier Departemental Vendee • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Can pictures help patients understand research better?
Knowledge-focused TerminatedThis study tested whether a visual consent form with pictures helps patients with cancer or Alzheimer's understand research better than standard text. Researchers planned to enroll 266 adults across three U.S. sites. The trial was terminated early, so results may be limited.
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Tiny brain wave study aims to sharpen Alzheimer's drug testing
Knowledge-focused TerminatedThis pilot study measured brain activity (EEG) in 6 healthy volunteers while they performed computer tasks that test attention and memory. The goal was to develop better ways to measure thinking skills that could be used in future Alzheimer's drug trials. The study was terminated…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Alzheimer's study probes why patients struggle with daily choices
Knowledge-focused TerminatedThis study looked at how early Alzheimer's disease affects a person's ability to make decisions. Researchers tested 100 people with Alzheimer's and healthy volunteers using memory and thinking tasks, plus a special decision-making test. The goal was to understand which brain func…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Alzheimer's drug memantine tested on healthy brains – but study halted early
Knowledge-focused TerminatedThis early-stage study aimed to see if taking memantine, an Alzheimer's drug, for 15 days would change certain brain and cognitive markers in healthy young men aged 18-30. The goal was to validate a test battery for future Alzheimer's drug development. However, the study was term…
Phase: PHASE1 • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Mental health study aims to uncover Long-Term heart risks
Knowledge-focused TerminatedThis study followed 167 adults with mental health issues like anxiety, depression, or sleep problems who visited their primary care doctor. Researchers used health conversations and a blood test to track lifestyle changes and heart disease risks over up to 20 years. The goal was …
Phase: NA • Sponsor: Region Skane • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New tool aims to help seniors with dementia make safer choices about guns
Knowledge-focused TerminatedThis pilot study tested a decision aid designed to help older adults with early dementia or depression think about safer ways to store firearms at home. Only 5 people took part, and the study was ended early. The goal was to see if the tool was practical and acceptable, and wheth…
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Zapping the brain to save memories: Alzheimer's study tests new approach
Knowledge-focused TerminatedThis study explored whether a non-invasive technique called transcranial magnetic stimulation (TMS) could improve memory in healthy older adults and those with mild memory problems due to Alzheimer's. Researchers used TMS to stimulate brain networks linked to memory and measured …
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Robot watchdog: could a roaming robot prevent falls in dementia care?
Knowledge-focused TerminatedThis study tested whether a robot that moves on its own could patrol nursing home rooms and detect when a resident with Alzheimer's has fallen. The robot was designed to turn on lights, alert staff, and let them see and talk to the resident through its camera and screen. The stud…
Sponsor: Vigorous Mind, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Home help for dementia caregivers: study ends early with few answers
Knowledge-focused TerminatedThis study aimed to see if introducing formal home help (like a paid aide) improves the quality of life for people caring for elderly relatives with memory or thinking problems. Researchers planned to follow 12 caregivers for 90 days, measuring changes in their well-being, stress…
Sponsor: Groupe Hospitalier de la Region de Mulhouse et Sud Alsace • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Rare disease mystery: scientists watch AMN progress in hopes of finding a cure
Knowledge-focused TerminatedThis study followed 65 adult men with a rare inherited nerve disease called AMN (a form of spastic paraplegia) to understand how their symptoms change over time. Researchers collected data on walking ability and quality of life. The goal was to fill gaps in knowledge about the di…
Sponsor: SwanBio Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Alzheimer's Anti-Inflammatory trial halted early – what we learned
Knowledge-focused TerminatedThis study tested whether anti-inflammatory drugs could help people with early Alzheimer's or mild cognitive impairment. It was stopped early, so only one drug was studied in 34 participants. The main goal was to measure changes in thinking and memory, but the early termination l…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC